Point72 Asset Management
CATX icon

Point72 Asset Management’s Perspective Therapeutics CATX Stock Holding History

Point72 Asset Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-314,180
Closed -$864K – 3831
2025
Q4 		$864K Buy
314,180
+269,947
+610% +$770K ﹤0.01% 2948
2025
Q3 		$152K Sell
44,233
-15,788
-26% -$57.6K ﹤0.01% 2172
2025
Q2 		$206K Buy
+60,021
New +$158K ﹤0.01% 1978
2025
Q1 		– Sell
-54,893
Closed -$175K – 2085
2024
Q4 		$175K Buy
+54,893
New +$448K ﹤0.01% 1915
2024
Q3 		– Sell
-202,572
Closed -$2.02M – 2006
2024
Q2 		$2.02M Sell
202,572
-1,142,754
-85% -$16.5M 0.01% 1092
2024
Q1 		$16M Buy
+1,345,326
New +$11.5M 0.04% 537

Other funds holding CATX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management's CATX Position: Q1 2026 in Review

Point72 Asset Management sold out of Perspective Therapeutics (CATX) in Q1 2026, closing a stake of 314,180 shares — an estimated $864K sold.

Point72 Asset Management first reported a position in CATX in Q1 2024 and held it in 6 quarters. The position peaked at $16M in Q1 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Point72 Asset Management reported no remaining Perspective Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 314,180 Perspective Therapeutics shares in Q1 2026, an estimated $864K.
  • Point72 Asset Management first reported a position in Perspective Therapeutics in Q1 2024 and held it in 6 quarters.
  • Point72 Asset Management's Perspective Therapeutics position peaked at $16M in Q1 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.